ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2013
The immune microenvironment of human tumors: general significance and clinical impact.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Tumor Microenvironment in Sporadic Vestibular Schwannoma: A Systematic, Narrative Review.International journal of molecular sciences · 2023Pooled it
- Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis.British journal of cancer · 2019Pooled it
- Immunosenescence shapes the tumor immune microenvironment and limits PD-1/PD-L1 blockade efficacy in older patients with cancer.Frontiers in immunology · 2026Review
- Complement system in tumor growth and metastases.British journal of cancer · 2026Review
- Gallbladder Schwannoma: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Current molecular understanding of central nervous system schwannomas.Acta neuropathologica communications · 2025Review
- Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature.World journal of gastrointestinal oncology · 2025Article
- Prognostic Significance of Regulatory CD25+ T Cells in Bladder Cancer: An Immunohistochemical Analysis.Turk patoloji dergisi · 2025Article
- IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells.Frontiers in immunology · 2025Article
- Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications.Cancers · 2024Review
- Failed Induction of the TIntegrative medicine (Encinitas, Calif.) · 2024Article
- Pro-cancer and conditional anti-cancer effects of TCA cycle breaks.Integrative medicine (Encinitas, Calif.) · 2024Article
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Article
- Article
- Genomic and immunogenomic analysis of three prognostic signature genes in LUAD.BMC bioinformatics · 2023Article
- Article
- High infiltration of CD209Frontiers in immunology · 2023Article
- Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models.BioImpacts : BI · 2023Article
- Induction of pyroptotic cell death as a potential tool for cancer treatment.Journal of inflammation (London, England) · 2022Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cancers grow in a microenvironment of stromal, inflammatory and immunocompetent cells which is variable from tumor to tumor. The characterization of the immune contexture, i.e. the type, density and functional orientation of immunocompetent cells, the presence or absence of tertiary lymphoid structures is a major prognostic factor for patients survival and represent a guide and a target for innovative cancer therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.